Pulmatrix Operating Cycle from 2010 to 2026

PULM Stock  USD 2.57  0.05  1.91%   
Pulmatrix Operating Cycle yearly trend continues to be very stable with very little volatility. Operating Cycle is likely to grow to 96.83 this year. During the period from 2010 to 2026, Pulmatrix Operating Cycle quarterly data regression pattern had sample variance of  9,583 and median of  96.83. View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
53.37
Current Value
96.83
Quarterly Volatility
97.89340679
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Pulmatrix financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pulmatrix's main balance sheet or income statement drivers, such as Interest Expense of 197.6 K, Other Operating Expenses of 19 M or Research Development of 11.1 M, as well as many indicators such as Price To Sales Ratio of 3.57, Dividend Yield of 0.13 or PTB Ratio of 3.11. Pulmatrix financial statements analysis is a perfect complement when working with Pulmatrix Valuation or Volatility modules.
  
Build AI portfolio with Pulmatrix Stock
Check out the analysis of Pulmatrix Correlation against competitors.
To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.
Evaluating Pulmatrix's Operating Cycle across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Pulmatrix's fundamental strength.

Latest Pulmatrix's Operating Cycle Growth Pattern

Below is the plot of the Operating Cycle of Pulmatrix over the last few years. It is Pulmatrix's Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pulmatrix's overall financial position and show how it may be relating to other accounts over time.
Operating Cycle10 Years Trend
Slightly volatile
   Operating Cycle   
       Timeline  

Pulmatrix Operating Cycle Regression Statistics

Arithmetic Mean115.53
Geometric Mean58.48
Coefficient Of Variation84.74
Mean Deviation72.63
Median96.83
Standard Deviation97.89
Sample Variance9,583
Range331
R-Value(0.34)
Mean Square Error9,056
R-Squared0.11
Significance0.18
Slope(6.55)
Total Sum of Squares153,330

Pulmatrix Operating Cycle History

2026 96.83
2025 53.37
2023 46.41
2022 81.1
2021 4.73
2020 2.43

About Pulmatrix Financial Statements

Pulmatrix investors utilize fundamental indicators, such as Operating Cycle, to predict how Pulmatrix Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Operating Cycle 53.37  96.83 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Pulmatrix is a strong investment it is important to analyze Pulmatrix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pulmatrix's future performance. For an informed investment choice regarding Pulmatrix Stock, refer to the following important reports:
Check out the analysis of Pulmatrix Correlation against competitors.
To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.
You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Will Pharmaceuticals sector continue expanding? Could Pulmatrix diversify its offerings? Factors like these will boost the valuation of Pulmatrix. Anticipated expansion of Pulmatrix directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Pulmatrix data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(1.71)
Revenue Per Share
0.001
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.47)
Return On Equity
(0.79)
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Pulmatrix's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pulmatrix should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Pulmatrix's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.